Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D

Aaron Z. Priluck, Shane J Havens

Research output: Contribution to journalArticle

Abstract

Objective: Determine the prices and price variation of the prostaglandin analogs (PGAs) used in the United States and examine their trends from 2013-2016 using Medicare Part D data. Design: Retrospective cross-sectional study. Participants: All ophthalmologists and optometrists in all fifty states and D.C. who prescribed any PGA purchased through Part D from 2013 through 2016. Methods: Outcome measures were calculated using Excel 2016 based off of the 2013-2016 Medicare Part D Prescriber Data. Main Outcome Measures: 2013-2016 nationwide prices of seven PGAs, the states with the 2016 minimum and maximum average prices, the standard deviations in PGA prices among the cities in each state, and the nationwide average of these standard deviations for 2013-2016. Results: The 2016 nationwide prices of 30-day supplies of bimatoprost, latanoprost, Lumigan, Travatan Z, travoprost, Xalatan, and Zioptan in 2016 were: $107.90±25.19, $10.16±1.52, $167.30±17.66, $171.36±19.44, $92.53±15.14, $153.41±15.16, and $162.75±13.22 respectively. Each drug's standard deviation in city prices within each state averaged nationwide for 30-day supplies in 2016 were $10.89, $1.44, $16.68, $17.23, $10.30, $10.07, and $9.48 respectively. Spending on these drugs totaled $861,180,924 in 2016. There was less price variation within each state as compared to the whole country. No substantial decreases in price variation exist for any drug from 2013-2016. Conclusions: There is substantial variation in PGA prices when purchased by Medicare Part D enrollees across the United States and within each state itself. Simultaneously, the prices and total expenditure on these medications are increasing yearly. Physicians should be cognizant of this price variation for these expensive and chronically used drugs and should educate patients to optimize their Part D supplemental plan.

Original languageEnglish (US)
JournalJournal of Glaucoma
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Medicare Part D
Synthetic Prostaglandins
latanoprost
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Health Expenditures

Keywords

  • cost reduction
  • drug costs
  • drug variability
  • glaucoma
  • glaucoma adherence
  • glaucoma compliance
  • healthcare optimization
  • medicare
  • medicare part D
  • medication adherence
  • medication compliance
  • part D
  • price variation
  • prostaglandin analogs

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D. / Priluck, Aaron Z.; Havens, Shane J.

In: Journal of Glaucoma, 01.01.2018.

Research output: Contribution to journalArticle

@article{2fb742ec4b0f414ead72e565b7229483,
title = "Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D",
abstract = "Objective: Determine the prices and price variation of the prostaglandin analogs (PGAs) used in the United States and examine their trends from 2013-2016 using Medicare Part D data. Design: Retrospective cross-sectional study. Participants: All ophthalmologists and optometrists in all fifty states and D.C. who prescribed any PGA purchased through Part D from 2013 through 2016. Methods: Outcome measures were calculated using Excel 2016 based off of the 2013-2016 Medicare Part D Prescriber Data. Main Outcome Measures: 2013-2016 nationwide prices of seven PGAs, the states with the 2016 minimum and maximum average prices, the standard deviations in PGA prices among the cities in each state, and the nationwide average of these standard deviations for 2013-2016. Results: The 2016 nationwide prices of 30-day supplies of bimatoprost, latanoprost, Lumigan, Travatan Z, travoprost, Xalatan, and Zioptan in 2016 were: $107.90±25.19, $10.16±1.52, $167.30±17.66, $171.36±19.44, $92.53±15.14, $153.41±15.16, and $162.75±13.22 respectively. Each drug's standard deviation in city prices within each state averaged nationwide for 30-day supplies in 2016 were $10.89, $1.44, $16.68, $17.23, $10.30, $10.07, and $9.48 respectively. Spending on these drugs totaled $861,180,924 in 2016. There was less price variation within each state as compared to the whole country. No substantial decreases in price variation exist for any drug from 2013-2016. Conclusions: There is substantial variation in PGA prices when purchased by Medicare Part D enrollees across the United States and within each state itself. Simultaneously, the prices and total expenditure on these medications are increasing yearly. Physicians should be cognizant of this price variation for these expensive and chronically used drugs and should educate patients to optimize their Part D supplemental plan.",
keywords = "cost reduction, drug costs, drug variability, glaucoma, glaucoma adherence, glaucoma compliance, healthcare optimization, medicare, medicare part D, medication adherence, medication compliance, part D, price variation, prostaglandin analogs",
author = "Priluck, {Aaron Z.} and Havens, {Shane J}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/IJG.0000000000001096",
language = "English (US)",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Variation in Prostaglandin Analog Prices Paid for Through Medicare Part D

AU - Priluck, Aaron Z.

AU - Havens, Shane J

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Determine the prices and price variation of the prostaglandin analogs (PGAs) used in the United States and examine their trends from 2013-2016 using Medicare Part D data. Design: Retrospective cross-sectional study. Participants: All ophthalmologists and optometrists in all fifty states and D.C. who prescribed any PGA purchased through Part D from 2013 through 2016. Methods: Outcome measures were calculated using Excel 2016 based off of the 2013-2016 Medicare Part D Prescriber Data. Main Outcome Measures: 2013-2016 nationwide prices of seven PGAs, the states with the 2016 minimum and maximum average prices, the standard deviations in PGA prices among the cities in each state, and the nationwide average of these standard deviations for 2013-2016. Results: The 2016 nationwide prices of 30-day supplies of bimatoprost, latanoprost, Lumigan, Travatan Z, travoprost, Xalatan, and Zioptan in 2016 were: $107.90±25.19, $10.16±1.52, $167.30±17.66, $171.36±19.44, $92.53±15.14, $153.41±15.16, and $162.75±13.22 respectively. Each drug's standard deviation in city prices within each state averaged nationwide for 30-day supplies in 2016 were $10.89, $1.44, $16.68, $17.23, $10.30, $10.07, and $9.48 respectively. Spending on these drugs totaled $861,180,924 in 2016. There was less price variation within each state as compared to the whole country. No substantial decreases in price variation exist for any drug from 2013-2016. Conclusions: There is substantial variation in PGA prices when purchased by Medicare Part D enrollees across the United States and within each state itself. Simultaneously, the prices and total expenditure on these medications are increasing yearly. Physicians should be cognizant of this price variation for these expensive and chronically used drugs and should educate patients to optimize their Part D supplemental plan.

AB - Objective: Determine the prices and price variation of the prostaglandin analogs (PGAs) used in the United States and examine their trends from 2013-2016 using Medicare Part D data. Design: Retrospective cross-sectional study. Participants: All ophthalmologists and optometrists in all fifty states and D.C. who prescribed any PGA purchased through Part D from 2013 through 2016. Methods: Outcome measures were calculated using Excel 2016 based off of the 2013-2016 Medicare Part D Prescriber Data. Main Outcome Measures: 2013-2016 nationwide prices of seven PGAs, the states with the 2016 minimum and maximum average prices, the standard deviations in PGA prices among the cities in each state, and the nationwide average of these standard deviations for 2013-2016. Results: The 2016 nationwide prices of 30-day supplies of bimatoprost, latanoprost, Lumigan, Travatan Z, travoprost, Xalatan, and Zioptan in 2016 were: $107.90±25.19, $10.16±1.52, $167.30±17.66, $171.36±19.44, $92.53±15.14, $153.41±15.16, and $162.75±13.22 respectively. Each drug's standard deviation in city prices within each state averaged nationwide for 30-day supplies in 2016 were $10.89, $1.44, $16.68, $17.23, $10.30, $10.07, and $9.48 respectively. Spending on these drugs totaled $861,180,924 in 2016. There was less price variation within each state as compared to the whole country. No substantial decreases in price variation exist for any drug from 2013-2016. Conclusions: There is substantial variation in PGA prices when purchased by Medicare Part D enrollees across the United States and within each state itself. Simultaneously, the prices and total expenditure on these medications are increasing yearly. Physicians should be cognizant of this price variation for these expensive and chronically used drugs and should educate patients to optimize their Part D supplemental plan.

KW - cost reduction

KW - drug costs

KW - drug variability

KW - glaucoma

KW - glaucoma adherence

KW - glaucoma compliance

KW - healthcare optimization

KW - medicare

KW - medicare part D

KW - medication adherence

KW - medication compliance

KW - part D

KW - price variation

KW - prostaglandin analogs

UR - http://www.scopus.com/inward/record.url?scp=85053849298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053849298&partnerID=8YFLogxK

U2 - 10.1097/IJG.0000000000001096

DO - 10.1097/IJG.0000000000001096

M3 - Article

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

ER -